Prosecution Insights
Last updated: April 19, 2026
Application No. 18/001,516

SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA

Non-Final OA §102§112
Filed
Dec 12, 2022
Examiner
CHEN, PO-CHIH
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Icahn School Of Medicine AT Mount Sinai
OA Round
1 (Non-Final)
75%
Grant Probability
Favorable
1-2
OA Rounds
2y 7m
To Grant
88%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allow Rate
553 granted / 740 resolved
+14.7% vs TC avg
Moderate +14% lift
Without
With
+13.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
52 currently pending
Career history
792
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
27.5%
-12.5% vs TC avg
§102
20.0%
-20.0% vs TC avg
§112
31.8%
-8.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 740 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAIL ACTION This office action is a response to a 371 application filed 12/12/2022, which is a national stage application of PCT/US21/37405 filed 6/15/2021, which claims domestic priority to 63/039,704 filed 6/16/2020. As filed, claims 1-15 are pending. Election/Restrictions Applicant’s election without traverse of Group I – Claims 1-5 and 10-15 in the reply filed on 11/14/2025 is acknowledged. Claims 6-9 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 11/14/2025. Regarding the election of species requirement, Applicant elected the species of PNG media_image1.png 150 314 media_image1.png Greyscale , which is found on pg. 186 of the instant specification. The claims, which read on the elected species, are instant claims 1-5 and 10, according to Applicant’s reply filed 11/14/2025. Claims 11-15 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Examination will begin with the elected species. In accordance with the MPEP 803.02, if upon examination of the elected species, no prior art is found that would anticipate or render obvious the instant invention based on the elected species, the search of the Markush-type claim will be extended. If prior art is then found that anticipates or renders obvious the non-elected species, the Markush-type claim will be rejected. It should be noted that the prior art search will not be extended unnecessarily to cover all non-elected species . Should Applicant overcome the rejection by amending the claim, the amended claim will be reexamined. Id. The prior art search will be extended to the extent necessary to determine patentability of the Markush-type claim. Id. In the event prior art is found during reexamination that renders obvious or anticipates the amended Markush-type claim, the claim will be rejected and the action made final. Id. As per MPEP 803.02, the Examiner will attempt to determine whether the entire scope of the claims is patentable. Applicants' elected species, as shown above, does makes a contribution over the prior art of record. Therefore, according to MPEP 803.02: should the elected species appear allowable, the search of the Markush-type claim will be extended. The search and examination should be continued until either (1) prior art is found that anticipates or renders obvious a species that falls within the scope of a proper Markush grouping that includes the elected species, or (2) it is determined that no prior art rejection of any species that falls within the scope of a proper Markush grouping that includes the elected species can be made. The Examiner need not extend the search beyond a proper Markush grouping. While searching for prior art on the elected species, prior art was found that anticipated other species encompassed by the claims. Both prior art rejections were made below in order to advance compact prosecution. Information Disclosure Statement The information disclosure statement (IDS) submitted on 12/12/2022; 10/9/2024; and 11/14/2025 has been considered by the Examiner. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 3, and 5 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 1, the claim failed to recite the definition for instant variables R10 and R11 for (iii), (iv), (v) and (vi), when the definition for instant variables R10 and R11 was recited for (i) and (ii). Accordingly, the metes and bounds of R10 and R11 are unclear for the structures recited in (iii), (iv), (v) and (vi). The claims are rendered indefinite. Regarding claims 3 and 5, these claims are dependent of claim 1, and they failed to correct the indefiniteness issue of claim 1, which rendered these claims indefinite. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-5 and 10 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Chemical Abstract Registry No. 1015369-39-7, hereinafter CAS397. Regarding claims 1-5 and 10, CAS397 teaches the following compound or pharmaceutical composition thereof (with unbuffered water), which meets all the limitation of these claims. PNG media_image2.png 210 392 media_image2.png Greyscale PNG media_image3.png 40 594 media_image3.png Greyscale Wherein in claims 1 and 10: instant variable Ar1 is PNG media_image4.png 172 250 media_image4.png Greyscale ; one of instant variables R1 and R2 is methyl, while the other is H; instant variable R3 is H; instant variable L is -CONH-; instant variable Ar2 is phenyl substituted by -SO2-R10; and instant variable R10 is unsubstituted phenyl-NH-. Where in claim 2: instant Ring A is PNG media_image5.png 144 166 media_image5.png Greyscale ; instant variable R4 is methyl; instant variables R5 and R6 taken together form =O; instant variable Q2 is S; instant variable Q1 is NH; instant variable L is -CONH-; instant variable R3 is H; instant variable R1 is H; and instant variable R2 is unsubstituted phenyl. Claims 1 and 3 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by PubChem substance No. SID398191177, hereinafter SID177. See IDS filed 12/12/2022. Regarding claims 1 and 3, SID177 teaches the following compound, which meets all the limitations of these claims. PNG media_image6.png 130 310 media_image6.png Greyscale Wherein: instant variable Ar1 is PNG media_image7.png 128 218 media_image7.png Greyscale ; instant variable Y5 is N; instant variableS Y6-Y8 are C; instant variable L is -CONH-; instant variable Ar2 is phenyl substituted by -SO2-R10; and instant variable R10 is unsubstituted phenyl-NH-. Claim Objections Claims 1, 3-5, and 10 are objected to because of the following informalities: Regarding claim 1, the claim recites two instances of “arylamino” for instant variable R10 and thus, the duplicate needs to be removed. Regarding claim 1, the claim recites PNG media_image8.png 124 168 media_image8.png Greyscale , which appears to contain drawing error and can be corrected by reciting -- PNG media_image9.png 142 206 media_image9.png Greyscale --. Regarding claim 1, the claim recites the following phrase, which is not in proper form because it failed to recite for alternative. PNG media_image10.png 238 460 media_image10.png Greyscale Regarding claim 4, the claim, for instance, recites the following structure: PNG media_image11.png 120 242 media_image11.png Greyscale , wherein the bonds on the -S(O)2- looks like two dots and thus, need to be corrected for this structure, as well as all other structures that have the same issue. Regarding claims 3 and 10, the claims recite the phase, “A compound according to claim 1”. The expression can be clarified by reciting -- The compound according to claim 1 --. Regarding claim 5, the claim recites the phrase, “a compound according to claim 1”. Such expression can be clarified by reciting -- the compound according to claim 1 --. Appropriate correction is required. Conclusion Claims 1-5 and 10 are rejected. Claims 1, 3-5, and 10 are objected. Claims 6-9 and 11-15 are withdrawn. Telephone Inquiry Any inquiry concerning this communication or earlier communications from the examiner should be directed to PO-CHIH CHEN whose telephone number is (571)270-7243. The examiner can normally be reached Monday - Friday 10:00 am to 6:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks can be reached at (571)270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PO-CHIH CHEN/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Dec 12, 2022
Application Filed
Dec 13, 2025
Non-Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595225
METHOD FOR PRODUCING ASYMMETRIC LINEAR CARBONATE
2y 5m to grant Granted Apr 07, 2026
Patent 12582632
INHIBITION OF NEUROLOGICAL INJURIES DUE TO INFECTIONS VIA ADMINISTRATION OF BUTANETAP AND ANALOGS THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12571801
Tandem Activity-Based Sensing and Labeling Strategy for Reactive Oxygen Species Imaging
2y 5m to grant Granted Mar 10, 2026
Patent 12552792
SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME
2y 5m to grant Granted Feb 17, 2026
Patent 12552782
Analogs of Nitrofuran Antibiotics to Combat Resistance
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
75%
Grant Probability
88%
With Interview (+13.8%)
2y 7m
Median Time to Grant
Low
PTA Risk
Based on 740 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month